AIHTA - Publications - Search - Pembrolizumab (Keytruda®) as monotherapy for the treatment of microsatellite instability-high (MSI‑H) or mismatch repair deficient (dMMR) tumours in adults with unresectable or metastatic colorectal cancer, advanced or recurrent endometrial carcinoma and unresectable or metastatic gastric, small intestine, or biliary cancer

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) as monotherapy for the treatment of microsatellite instability-high (MSI‑H) or mismatch repair deficient (dMMR) tumours in adults with unresectable or metastatic colorectal cancer, advanced or recurrent endometrial carcinoma and unresectable or metastatic gastric, small intestine, or biliary cancer. Oncology Fact Sheet Nr. 90.

[thumbnail of Oncology Fact Sheet Nr.90.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
120kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WI Digestive system > WI 300-387 Stomach
WI Digestive system > WI 400-560 Intestines
WI Digestive system > WI 600-650 Anus. Rectum
WI Digestive system > WI 700-770 Liver. Billary tract
WP Gynaecology > WP 440-468 Uterine diseases
Language:English
Series Name:Oncology Fact Sheet Nr. 90
Deposited on:25 Apr 2022 14:54
Last Modified:16 May 2022 09:31

Repository Staff Only: item control page